Page 70 - ஜப்பான் அமைச்சகம் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
일본서 새로운 코로나 변이 바이러스 확인
hani.co.kr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hani.co.kr Daily Mail and Mail on Sunday newspapers.
일본서 또다른 변이 바이러스 발견…브라질 여행자 4명
nocutnews.co.kr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nocutnews.co.kr Daily Mail and Mail on Sunday newspapers.
已投入巨大成本 东奥等疫苗 救命 | 马来西亚诗华日报新闻网
seehua.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seehua.com Daily Mail and Mail on Sunday newspapers.
Font : A-A+
SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice
® Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula
® (niraparib). myChoice was approved by Japans Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication and the reimbursement decision is now in effect. Myriads myChoice test is the only one of its kind to be approved for reimbursement in Japan, said Nicole Lambert, president of Myriad Genetic Laboratories. This decision further advances precision medicine and helps ensure that more Japanese women have access to the most advanced therapies in their fight against ovarian cancer.
Posted January 8th, 2021 for Myriad SALT LAKE CITY, Jan. 08, 2021 ( ) Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice
® Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula
® (niraparib). myChoice was approved by Japan’s Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication and the reimbursement decision is now in effect. “Myriad’s myChoice test is the only one of its kind to be approved for reimbursement in Japan,” said Nicole Lambert, president of Myriad Genetic Laboratories. “This decision further advances precision medicine and helps ensure that more Japanese women have access to the most advanced therapies in their fight against ovarian cancer.”